Aluminum Oxide Bryonia Alba Root Casanthranol Citr
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aluminum Oxide Bryonia Alba Root Casanthranol Citr
- Homeopathic Multi-Ingredient Combination: TxGNN Prediction Unavailable
Homeopathic Multi-Ingredient Combination: TxGNN Prediction Unavailable
One-Sentence Summary
This entry represents a complex 11-ingredient homeopathic mixture — including botanical extracts (Bryonia alba, Lycopodium clavatum, Senna, Nux-vomica), mineral/chemical substances (Aluminum Oxide, Sulfur, Lead, Mercuric Chloride), and biological materials (Lachesis Muta Venom) — for which no original indication has been established in the regulatory record. The TxGNN model was unable to generate repurposing predictions, as the combination could not be mapped to a DrugBank entity; accordingly, no clinical trials or publications are linked to this candidate at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established (no regulatory approvals on record) |
| Predicted New Indication | Not available |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — Model prediction only; no actual studies (prediction not generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction was generated for this candidate. The pipeline could not resolve the multi-ingredient combination to a single DrugBank identifier, which is a prerequisite for the knowledge-graph and deep-learning prediction steps. As a result, no disease–drug association score exists, and no mechanistic rationale for repurposing can be derived at this time.
The ingredient list follows the pattern of a homeopathic formulation: classical polycrest remedies (Sulfur, Lycopodium clavatum, Lachesis muta, Nux-vomica, Bryonia alba) are combined with botanical cathartics (Senna leaf, Casanthranol, Citrullus colocynthis) and mineral substances (Aluminum Oxide, Lead, Mercuric Chloride). In homeopathic practice these are typically dispensed at extreme dilutions (e.g., 6X–30C), which nominally reduces the quantity of the source material to sub-pharmacological or undetectable levels. Whether the preparation in question is diluted to homeopathic potencies or used in material doses is unknown from the available data.
Because no mechanism of action, approved indication, or predictive output exists, the scientific basis for repurposing cannot be assessed with the current information.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No regulatory authorisations on record for this combination in the current dataset.
Safety Considerations
Although formal package-insert data is unavailable for this combination, the ingredient list itself warrants disclosure of the following known hazards at material (non-homeopathic) doses:
- Lead — established neurotoxin and nephrotoxin; no safe threshold for chronic exposure (IARC Group 2A for inorganic lead compounds).
- Mercuric Chloride — highly toxic heavy-metal compound; corrosive to mucous membranes; renal and CNS toxicity.
- Strychnos Nux-Vomica Seed — contains strychnine and brucine; potent glycine-receptor antagonists; narrow therapeutic index with risk of convulsions and respiratory failure.
- Lachesis Muta Venom — bushmaster snake venom; hemotoxic and cytotoxic at pharmacologically active concentrations.
- Citrullus Colocynthis Fruit Pulp — potent cathartic; can cause severe gastrointestinal irritation and fluid/electrolyte loss.
If this product is formulated at homeopathic dilutions, the pharmacological activity of the above substances is negligible by conventional pharmacokinetic standards. However, the dilution level and actual dose per unit are not confirmed in the evidence pack.
Drug interactions: No DDI data found for this combination.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline could not generate a repurposing prediction because the 11-ingredient combination lacks a DrugBank identifier; without a prediction, there is no evidence-based scientific rationale to evaluate, and the formulation raises unresolved safety questions regarding toxic-ingredient concentrations.
To proceed, the following is needed:
- Resolve ingredient identity: Confirm whether this is a homeopathic preparation (specify dilution potencies) or a material-dose combination product; this determines which regulatory pathway and safety framework applies.
- DrugBank mapping: Attempt individual ingredient-level DrugBank lookups and re-run TxGNN on the most pharmacologically active components (e.g., Casanthranol, Senna, Nux-vomica alkaloids separately).
- Regulatory clarification: Retrieve the TFDA/FDA product monograph or dossier to confirm the approved indication (if any), excipient concentrations, and dilution levels.
- Safety data: Obtain the package insert (or equivalent) to document contraindications, warnings, and any known interactions for each active ingredient.
- Toxicology review: Conduct a formal risk assessment for Lead and Mercuric Chloride content prior to any clinical-development discussion.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.